Impel Pharmaceuticals Inc. (IMPL) reported Q2 EPS of ($1.09), $0.04 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.84 million.
Impel Pharmaceuticals Inc. (IMPL) reported Q2 EPS of ($1.09), $0.04 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.84 million.